Particle Health says data dispute with Epic Systems not affecting most customers

Particle Health says data dispute with Epic Systems not affecting most customers


Joos Mind | Photodisc | Getty Images

Particle Health said on Monday that the “vast majority” of its customers are still receiving records from medical software giant Epic Systems despite an ongoing dispute between the two companies over data-sharing practices.

Epic’s software supports more than 300 million patient records, and Particle acts like a middleman that helps health-care organizations access the data they need. Both companies belong to an interoperability network called Carequality, which facilitates the exchange of patient information on a large scale.

On March 21, Epic filed a formal dispute with Carequality citing concerns that Particle and its participant organizations “might be inaccurately representing the purpose associated with their record retrievals.” In order to join the Carequality network, organizations are approved and must abide by “Permitted Purposes,” generally having to do with treatment, for the exchange of patient records

Patient data is protected by a federal law called the Health Insurance Portability and Accountability Act, or HIPAA, which requires a patient’s consent or knowledge for third-party access.

Particle said in a release Monday that while Epic “indiscriminately stopped responding” to data requests from some of its customers because of the dispute, most clients were not affected. The company said it’s been pressing Epic to restore connection to impacted customers, and many are already back to normal.

“While there is an ongoing dispute between Epic and Particle Health, related to three specific customers, the significant majority of Particle Health customers impacted by Epic’s actions were not in any way related to this dispute,” the company said in the release.

Particle CEO Jason Prestinario said in the statement that the company will address the dispute with Epic through official procedural channels.

Epic did not immediately respond to CNBC’s request for comment.

WATCH: Insurer stocks fall on Medicare rates

Health care stocks headed for worst day since early November



Source

Abbott stock fell victim to an old earnings season truth: It’s all about the guidance
Health

Abbott stock fell victim to an old earnings season truth: It’s all about the guidance

Shares of Abbott Laboratories fell Thursday after the diversified health-care company delivered a solid second quarter but left investors disappointed with forward guidance. Revenue in the three months ended June 30 rose 7.4% to $11.14 billion, outpacing the $11.07 billion consensus estimate, according to estimates compiled by LSEG. Organic sales , excluding Covid testing results, […]

Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Health

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]

Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Health

Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]

Read More